H.R. 3810 · 118th Congress (2023–2025)
Drug Origin Transparency Act of 2023
This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.
Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 3810’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Anna G. Eshoo (D-CA-16)
- Cosponsors
4 cosponsors
0 original · 4 later
- Rep. Angie Craig (D-MN-2)· Later · Jul 11, 2023
- Rep. John P. Sarbanes (D-MD-3)· Later · Jul 11, 2023
- Rep. Scott H. Peters (D-CA-50)· Later · Jul 25, 2023
- Rep. Tony Cárdenas (D-CA-29)· Later · Sep 13, 2023
- Policy area
- Health
- Subjects
- Consumer affairs
- Government information and archives
- Manufacturing
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Jun 5, 2023 – Jun 9, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Sep 14, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Drug Origin Transparency Act of 2023
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Official title · Introduced in House